Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a precision genetic medicine company whose news flow centers on the development of gene therapy candidates for rare neuromuscular and cardiac diseases. Company announcements highlight progress across multiple clinical programs, regulatory designations and collaborations related to its investigational therapies and platform technologies.
Investors and observers following SLDB news can expect updates on key clinical trials such as INSPIRE DUCHENNE and IMPACT DUCHENNE for SGT-003 in Duchenne muscular dystrophy, the FALCON Phase 1b trial of SGT-212 in Friedreich’s ataxia, and the ARTEMIS Phase 1b trial of SGT-501 for catecholaminergic polymorphic ventricular tachycardia. News items also describe interim clinical data, including safety, tolerability, biomarker changes and cardiac monitoring findings, as well as regulatory interactions and designations from agencies such as the U.S. Food and Drug Administration and U.K. authorities.
Solid Biosciences’ news releases additionally cover its proprietary AAV-SLB101 capsid platform, including data presentations at scientific meetings and licensing agreements with partners such as Andelyn Biosciences. Corporate updates, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in industry conferences like the J.P. Morgan Healthcare Conference also appear in the company’s news record.
This news page aggregates these disclosures so readers can review clinical milestones, regulatory developments, platform collaborations and corporate events related to Solid Biosciences and its SLDB stock over time.
Solid Biosciences (Nasdaq: SLDB) announced on December 1, 2025 that it granted a total of 23,284 restricted stock units (RSUs) to two newly hired employees as inducement awards under the company’s 2024 Inducement Stock Incentive Plan.
The RSUs vest in four equal installments on each one-year anniversary of the grant date through the fourth anniversary, and vesting is subject to the employees' continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced on Dec 1, 2025 that the FDA granted Rare Pediatric Disease designation to SGT-212, its investigational dual-route gene therapy for Friedreich’s ataxia (FA).
SGT-212 delivers the full-length frataxin gene via both intradentate nucleus (IDN) and intravenous (IV) administration and has previously received Fast Track designation. The Rare Pediatric Disease designation makes SGT-212 potentially eligible for a pediatric priority review voucher (PRV), which can expedite future biologics review or be sold or transferred. The company said screening is underway for the FALCON Phase 1b first-in-human trial.
Solid Biosciences (Nasdaq: SLDB) announced a non-exclusive worldwide license and collaboration with Andelyn Biosciences for Solid’s proprietary next-generation capsid AAV-SLB101 on Nov 17, 2025. The agreement lets Andelyn offer AAV-SLB101 to gene therapy clients via its AAV Curator® Platform; financial terms were not disclosed. AAV-SLB101 has shown robust preclinical cardiac and skeletal muscle transduction and, as of the safety cutoff on Oct 31, 2025, was generally well tolerated in 23 pediatric participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial (NCT06138639). Solid reports >30 existing agreements/licenses for AAV-SLB101, and the deal aims to broaden access to the capsid for early-stage programs.
Solid Biosciences (Nasdaq: SLDB) will participate in two investor conferences in late 2025 with senior management presenting in fireside chats.
- Jefferies Global Healthcare Conference (London) — Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will speak on Nov 18, 2025 at 11:00 a.m. GMT (6:00 a.m. ET).
- Piper Sandler 37th Annual Healthcare Conference — the same executives will speak on Dec 2, 2025 at 11:30 a.m. ET.
Live webcasts will be available on the company Investors Events page, and replay files will be archived there for 30 days. Institutional investors seeking one-on-one meetings should contact their Jefferies or Piper Sandler representatives.
Solid Biosciences (NASDAQ: SLDB) announced that SGT-003, its investigational gene therapy for Duchenne muscular dystrophy, was granted an Innovation Passport under the UK Innovative Licensing and Access Pathway (ILAP) on November 6, 2025. The Passport activates MHRA and ILAP partner agencies to develop a product-specific roadmap intended to accelerate regulatory timelines and patient access in the UK.
SGT-003 is one of the first three products in the new ILAP. Clinical development continues: the Phase 1/2 INSPIRE DUCHENNE trial is enrolling across 15 sites in the US, UK, Italy and Canada, and Solid has activated the first site and begun screening for the ex-US Phase 3 IMPACT DUCHENNE trial.
Solid Biosciences (Nasdaq: SLDB) announced on Nov. 4, 2025 that it granted a total of 26,550 restricted stock units (RSUs) to two newly hired employees as inducements under its 2024 Inducement Stock Incentive Plan.
The RSUs vest in four equal annual installments on each one‑year anniversary of the grant date through the fourth anniversary, and vesting is subject to each employee's continued service. The grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) reported Q3 2025 updates: 23 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial as of Oct 31, 2025, with an expectation to reach 30 participants by early 2026. The company plans an FDA meeting in H1 2026 to discuss potential registrational and accelerated pathways. Day 90 biopsy data (N=10) showed mean microdystrophin 58% (western blot and mass spectrometry) and mean beta-sarcoglycan 50%. Strong correlations observed with DAPC components (r=0.95) and CK reductions (r=-0.78). Cardiac markers trended toward normalized LVEF at Day 180 (N=8). Cash position: $236.1M, runway into H1 2027.
Solid Biosciences (Nasdaq: SLDB) announced it will participate in two investor conferences in November 2025. Dr. Gabriel Brooks, Chief Medical Officer will join a panel titled “Precision Medicine: DMD, FA, and Beyond” on November 6, 2025 at 1:40 p.m. ET at the Truist Securities BioPharma Symposium. Management will hold one-on-one investor meetings at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 10, 2025. Institutional investors should contact their Truist or Guggenheim representatives to request meetings.
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company focusing on neuromuscular and cardiac diseases, has granted 116,150 restricted stock units (RSUs) to four new employees. The RSUs will vest equally over four years, with 25% vesting on each anniversary of the grant date.
The equity awards were issued under the company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.
Solid Biosciences (NASDAQ:SLDB), a precision genetic medicines company, will present data from its neuromuscular and cardiac programs at two major scientific conferences in October 2025. The company will participate in the World Muscle Society (WMS) Annual Congress in Vienna and the European Society of Gene & Cell Therapy (ESGCT) Annual Congress in Seville.
The presentations include an oral update on the INSPIRE DUCHENNE Phase 1/2 study of SGT-003 for Duchenne Muscular Dystrophy, and multiple poster presentations covering muscle integrity biomarkers, gene therapy developments, and cardiac research. The company will showcase data demonstrating the potential of their proprietary AAV-SLB101 capsid technology.